Neukirch F, Korobaeff M, Verdier F, Timsit G, Fay M, Drutel P
Rev Inst Hyg Mines (Hasselt). 1978;33(4):191-5.
The authors made a study of the antihistaminic properties of Pipoxizine in 20 subjects with proven histaminic hyperreactivity. The design of the trial consisted in comparing the changes of VC, FEC1, expiratory airway resistance and V50 produced by a histamine aerosol given before and after administration of Pipoxizine. Pipoxizine was given by mouth to 10 patients and intravenously to the other 10 of the group. The statistical analysis of the results demonstrated an antagonist effect of Pipoxizine on the histamine induced bronchoconstriction. The data of this trial are confirmative of the results of other experimenters. It seems therefore reasonable to take into consideration the use of Pipoxizine in the preventive treatment of the paroxystic attacks of the asthmatic disease.
作者对20名已证实组胺反应性亢进的受试者进行了匹莫齐定抗组胺特性的研究。试验设计包括比较在给予匹莫齐定前后,组胺气雾剂引起的肺活量(VC)、第一秒用力呼气量(FEC1)、呼气气道阻力和50%肺活量时的呼气流量(V50)的变化。该组中的10名患者口服匹莫齐定,另外10名静脉注射。结果的统计分析表明,匹莫齐定对组胺诱导的支气管收缩有拮抗作用。该试验的数据证实了其他实验者的结果。因此,考虑将匹莫齐定用于哮喘病发作期的预防性治疗似乎是合理的。